List of Inomax drug patents
Inomax is owned by Mallinckrodt Hosp.
Inomax contains Nitric Oxide.
Inomax has a total of 30 drug patents out of which 0 drug patents have expired.
Inomax was authorised for market use on 23 December, 1999.
Inomax is available in gas;inhalation dosage forms.
Inomax can be used as a method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide, a method of providing a predetermined concentration of nitric oxide to a patient, a method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient, a method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitiric oxide as compared to the desired delivery concentration of nitric oxide, a method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient, a method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient.
The generics of Inomax are possible to be released after 03 November, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846112 | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Jun, 2029
(6 years from now) | |
| US8282966 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Jun, 2029
(6 years from now) | |
| US8293284 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Jun, 2029
(6 years from now) | |
| US8431163 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Jun, 2029
(6 years from now) | |
| US8795741 | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Jun, 2029
(6 years from now) | |
|
US8282966
(Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Dec, 2029
(6 years from now) | |
|
US8293284
(Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Dec, 2029
(6 years from now) | |
|
US8431163
(Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Dec, 2029
(6 years from now) | |
|
US8795741
(Pediatric) | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Dec, 2029
(6 years from now) | |
|
US8846112
(Pediatric) | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Dec, 2029
(6 years from now) | |
| US8776794 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(7 years from now) | |
| US8573210 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(7 years from now) | |
| US8573209 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
| US8776795 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
| US9408993 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(7 years from now) | |
| US9265911 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
| US9295802 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
| US8291904 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
|
US9265911
(Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(8 years from now) | |
|
US8776795
(Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(8 years from now) | |
|
US8776794
(Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(8 years from now) | |
|
US8573210
(Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(8 years from now) | |
|
US9295802
(Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(8 years from now) | |
|
US8291904
(Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(8 years from now) | |
|
US9408993
(Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(8 years from now) | |
|
US8573209
(Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(8 years from now) | |
| US9279794 | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Feb, 2034
(11 years from now) | |
|
US9279794
(Pediatric) | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Aug, 2034
(11 years from now) | |
| US9770570 | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
May, 2036
(13 years from now) | |
|
US9770570
(Pediatric) | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
Nov, 2036
(13 years from now) | |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide; A method of providing a predetermined concentration of nitric oxide to a patient; A method of treating hypoxic respiratory failure by verifying gas information of nitric oxide prior to delivery to patient; A method of providing nitric oxide therapy to a patient by verifying gas information of nitric oxide prior to delivery to patient; A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient; A method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitiric oxide as compared to the desired delivery concentration of nitric oxide
Dosage: GAS;INHALATION
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic